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Tuberculosis (TB) in humans is caused by members of theMycobacterium tuberculosis complex (MTC). Rapid
detection of the MTC is necessary for the timely initiation of antibiotic treatment, while differentiation between
members of the complex may be important to guide the appropriate antibiotic treatment and provide epide-
miological information. In this study, a multiplex real-time PCR diagnostics assay using novel molecular
targets was designed to identify the MTC while simultaneously differentiating between M. tuberculosis and M.
canettii. The lepA gene was targeted for the detection of members of the MTC, the wbbl1 gene was used for the
differentiation of M. tuberculosis and M. canettii from the remainder of the complex, and a unique region of the
M. canettii genome, a possible novel region of difference (RD), was targeted for the specific identification of M.
canettii. The multiplex real-time PCR assay was tested using 125 bacterial strains (64 MTC isolates, 44
nontuberculosis mycobacteria [NTM], and 17 other bacteria). The assay was determined to be 100% specific
for the mycobacteria tested. Limits of detection of 2.2, 2.17, and 0.73 cell equivalents were determined for M.
tuberculosis/M. canettii, the MTC, and M. canettii, respectively, using probit regression analysis. Further
validation of this diagnostics assay, using clinical samples, should demonstrate its potential for the rapid,
accurate, and sensitive diagnosis of TB caused by M. tuberculosis, M. canettii, and the other members of
the MTC.
Tuberculosis (TB) is the leading cause of death worldwide
from an infectious agent (13), with the WHO estimating that
one-third of the global population is infected with Mycobacte-
rium tuberculosis. In a global report from the WHO (2009), it
was estimated that there were 9.27 million cases of TB in 2007,
with 2 million associated deaths (41a). TB in humans is caused
by members of the Mycobacterium tuberculosis complex
(MTC). The eight closely related species of the MTC have a
wide range of natural hosts, including human hosts (M. tuber-
culosis, M. africanum, M. canettii), bovine hosts (M. bovis),
caprine hosts (M. caprae), rodent hosts (M. microti), and pin-
niped hosts (M. pinnipedii), along with the attenuated M. bovis
strain BCG (Bacillus Calmette-Gue´rin), the commonly used
vaccine strain. While there are a number of natural hosts, each
species of the MTC has been implicated in human infection (6,
20).
Traditionally, diagnosis of TB relies on smear microscopy
and culture techniques in combination with a battery of bio-
chemical tests which are time-consuming and labor-intensive
and which often yield unreliable results (18). Nucleic acid
diagnostic (NAD) techniques, in particular, real-time PCR,
offer rapid, reliable, and highly sensitive alternative tools for
the detection of many infectious agents (25, 42). Advances in
real-time PCR, such as the availability of multiple fluoro-
phores, along with the development of nonfluorescent quench-
ers, have facilitated multiplexing, allowing the simultaneous
detection and differentiation of multiple targets, along with
internal controls, in one reaction (3).
While significant advances have been made in the diagnosis
of TB using NAD techniques (19), the differentiation of mem-
bers of the MTC to the species level is not routinely per-
formed. Commercially available real-time PCR kits for the
diagnosis of TB generally identify the MTC but not individual
species. The high degree of nucleotide sequence homology
between members of the complex makes species differentiation
challenging (31). Comparative genomics revealed that the M.
tuberculosis and M. bovis genomes are 99.95% similar at the
nucleotide level (14), with whole-genome DNA microarrays
identifying 16 regions of difference (RD1 to RD16) (4). These
RDs represent regions of the genome which are deleted in M.
bovis BCG but which are present in M. tuberculosis and have
been used for the differentiation of members of the MTC. One
RD commonly targeted for the specific detection of M. tuber-
culosis is RD9 (31); however, this RD is also present in M.
canettii (7). There is currently no real-time PCR test which can
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diagnose TB while differentiating between M. tuberculosis and
M. canettii as the causative agent of infection.
M. tuberculosis is the most important human pathogen in the
MTC and is thought to be responsible for 95% of human cases
of TB, yet it rarely causes disease in other mammals (1, 7, 9).
While drug-resistant strains of M. tuberculosis are emerging, it
is considered sensitive to antituberculosis drugs such as pyrazin-
amide (PZA), a first-line antibiotic that reduces patient treat-
ment time from 9 months to 6 months (27, 35). However, M.
canettii, which has been reported to cause TB in humans, is
intrinsically resistant to PZA; therefore, the ability to differ-
entiate it from M. tuberculosis is important for indicating the
therapeutic regimen necessary for patient treatment (34).
M. canettii is considered to be the most phenotypically dis-
tinct member of the MTC and is considered the species from
which other members of the complex may have evolved (6). M.
canettii is phenotypically characterized by its smooth glossy
white colonies; however, a small number of these colonies have
been shown to revert to rough colony variants when individual
colonies are replated (38). Smooth colonies are uncharacter-
istic of the MTC and are due to the presence of large amounts
of lipooligosaccharides in the M. canettii cell wall (30). Like M.
tuberculosis, M. canettii contains all the RDs with the exception
of RD12 M. canettii (RD12can), which has been targeted for the
specific detection of M. canettii in a complex conventional PCR
methodology (18).
While infection with M. canettii is thought to be rare and
confined to eastern African countries, there is a lack of rapid
diagnostic tests available to differentiate between it and M.
tuberculosis. Cases of human TB caused by M. canettii have
now been reported in Europe and America (12). In addition,
recent reports have suggested that the number of true cases of
TB caused by M. canettii may in fact be underrepresented (15,
34). Therefore, an ability to differentiate M. tuberculosis and M.
canettii not only is important from a patient treatment perspec-
tive but also will provide important epidemiological informa-
tion for clinicians.
We report on the design, development, and testing of a
multiplex real-time PCR assay using novel nucleic acid diag-
nostics targets to detect the MTC while simultaneously detect-
ing and differentiating between M. tuberculosis and M. canettii
in one reaction.
MATERIALS AND METHODS
Diagnostics target identification. The diagnostics target genes used in this
study were identified using a number of approaches. In order to identify a target
for collective detection of the MTC, a number of housekeeping genes which are
highly conserved throughout the Mycobacterium genus were evaluated. To iden-
tify novel targets for the detection of M. tuberculosis, approximately 3,000 genes
were evaluated on the basis of regions deleted in other members of the MTC but
present in M. tuberculosis or, alternatively, present in other members of the MTC
but deleted in M. tuberculosis. These potential target regions were identified
using the Mycobacterial Genome Divergence Database (MGDD; http://mirna
.jnu.ac.in/mgdd/), which allowed identification of insertions, deletions, and single
nucleotide polymorphisms between M. tuberculosis, M. bovis, and M. bovis BCG.
Potential target regions were also identified using the web-based version of the
Artemis comparison tool, WebACT (http://www.webact.org/WebACT/home).
Nucleotide sequence information was retrieved from the M. africanum and M.
microti genomes (currently being sequenced by the Welcome Trust Sanger In-
stitute) to determine, in silico, if the candidate diagnostics target nucleotide
sequences for M. tuberculosis identification were specific. For the remaining
members of the complex, namely, M. canettii, M. caprae, and M. pinnipedii, for
which no nucleotide sequence information was available at the time of this study,
the specificities of potential targets for these species were determined empirically
and further validated through sequencing.
As the diagnostics target used in this study for the specific detection of M.
tuberculosis was experimentally determined to also detect M. canettii, a novel
diagnostics target specific for M. canettii was also required. When nucleotide
sequence information for M. canettii became publicly available on the Sanger
website, a number of large regions of nucleotide sequence were evaluated for
putative species-specific nucleotide sequence diagnostics motifs using the
BLAST program.
For each putative diagnostics target identified, alignments were carried out
using the ClustalW multiple-sequence alignment program (http://www.ebi.ac.uk
/Tools/clustalw2/index.html), from which real-time PCR primers and probes
were designed (Table 1).
Bacterial strains, culture media, and growth conditions. Sixty-four MTC iso-
lates (26 M. tuberculosis, 11 M. bovis, 7 M. bovis BCG, 5 M. canettii, 2 M. caprae,
5 M. africanum, 5 M. microti, and 3 M. pinnipedii isolates), 44 nontuberculosis
mycobacteria (NTM), and 17 other bacterial species were used in this study (see
Tables S1 and S2 in the supplemental material). Of the 64 MTC isolates, 36
strains, previously characterized by a variety of methods as described in the
TABLE 1. Oligonucleotide primers and probes used in this study
Name Function Sequence (533)
MTC_IAC Fw Forward sequencing primer, forward MTC and internal control
real-time PCR assay primer
AGACCGTGCGGATCTTG
MTC_IAC Rv Reverse sequencing primer, reverse MTC and internal control
real-time PCR assay primer
CATGGAGATCACCCGTGA
MTC probe MTC probe HEX-ACGGATTGGTCACCCGGATT-BHQ1
IAC probe Internal control probe Cy5-ACGACCTTCTCGGAACCGT-BHQ2
wbbl1_Fw Forward sequencing primer, forward real-time PCR assay primer TACCAGCTTCAGTTTCCGT
wbbl1_Rv Reverse sequencing primer, reverse real-time PCR assay primer GCACCTATATCTTCTTAGCCG
wbbl1 probe wbbl1 probe FAM-ATGGTGCGCAGTTCACTGC-BHQ1
M. canettii sp Fw Forward M. canettii-specific primer ATGTGGTTTCAGTACGACTTC
M. canettii sp Rv Reverse M. canettii-specific primer GATGGCAGTGTCTTATCCAA
M. canettii sp probe M. canettii-specific probe ROX-TGAGAGGTGTTGGCACGCAA-BHQ2
M. canettii seq 1.a Forward sequencing primer 1 TGTCGGCGGCCACGT
M. canettii seq 1.b Reverse sequencing primer 1 GAAGTCCAGCATCTTGGCGTT
M. canettii seq 2.a Forward sequencing primer 2 TGTCGGCGGCCACGT
M. canettii seq 2.b Reverse sequencing primer 2 ATCGTGCAGTGCGGCCA
M. canettii seq 3.a Forward sequencing primer 3 GCAGCATTGTGGTTGACCGA
M. canettii seq 3.b Reverse sequencing primer 3 TCCCAGCGTTGCGCCTT
M. canettii seq 4.a Forward sequencing primer 4 TGATGCGGCTGCTCAAGC
M. canettii seq 4.b Reverse sequencing primer 4 TGTCAAGGGACATGGGGAACT
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literature (12, 22, 23, 26, 30, 37–39), were provided by Dick van Soolingen
(RIVM, Bilthoven, Netherlands). All other MTC strains, provided by Mario
Vaneechoutte (University of Ghent, Ghent, Belgium), were clinical isolates
collected over a 10-year period from reference laboratories in Belgium and the
Netherlands. These isolates were characterized on the basis of custom techniques
available at the time. Twenty-eight NTM were purchased from the German
Collection of Microorganisms and Cell Cultures (Deutsche Sammlung von Mikro-
organismen und Zellkulturen GmbH [DSMZ]) and grown on Middlebrook agar/
broth at either 30°C or 37°C. Fast-growing mycobacteria were cultured for 3 to
6 days, and slow-growing mycobacteria were incubated for 6 weeks or until
sufficient growth was visible. All media were purchased from BD Biosciences
(Oxford, United Kingdom). For the 16 remaining NTM, in addition to 4 of the
5 Nocardia strains used in this study, DNA was supplied by Mario Vaneechoutte
and had been characterized using techniques previously described (10, 36, 41).
DNA isolation and quantification. Genomic DNA from NTM and 2 M. bovis
BCG cultures was isolated from 1 ml of culture (Middlebrook 7H9 broth; Becton
Dickinson), using a modified procedure combining mechanical lysis (IDI lysis kit;
GeneOhm, Quebec City, Quebec, Canada) and purification using a DNeasy
blood and tissue kit (Qiagen, Hilden, Germany). Briefly, 1 ml of culture was
centrifuged in a benchtop centrifuge (microcentrifuge 5415; Eppendorf) at
13,000 rpm for 3 min. The supernatant was discarded and the pellet was resus-
pended in 250 l GeneOhm sample buffer. The suspension was transferred to a
GeneOhm lysis tube and bead beaten (Mini-Bead-Beater-16; Stratech, United
Kingdom) for 3 min. After bead beating, 200 l was transferred to a sterile
microcentrifuge tube and steps 3 to 8 of the procedure for purification of total
DNA from animal tissue in the Qiagen DNeasy blood and tissue kit were
followed, according to the manufacturer’s instructions. The total genomic DNA
samples provided by RIVM were extracted using methods previously described
(40), while genomic DNA from Mario Vaneechoutte was extracted as described
in a study by De Baere et al. (10). For all other bacterial species tested, DNA was
provided from stocks held within the Microbiology laboratory of the National
University of Ireland, Galway. DNA concentrations for all NTM and members of
the MTC used in this study were determined using a PicoGreen double-stranded
DNA quantitation kit (Molecular Probes, Eugene, OR) and a TBS-380 miniflu-
orometer (Invitrogen Corporation, CA). All DNA samples were stored at20°C
before use.
Conventional and real-time PCR primers and hydrolysis probe design. Oligo-
nucleotide primers and hydrolysis probes were designed in accordance with
general recommendations and guidelines (11, 33), following the alignments of
each of the nucleic acid diagnostics target genes identified in this study. All
primers and probes (Table 1) used in this study were supplied by MWG-Biotech
AG (Essenberg, Germany). The primers used in this study were designed to have
a melting temperature (Tm) of 58 to 61°C, with all probes designed to have a Tm
of 4 to 7°C higher. Hydrolysis probes were designed to be specific for each target
following published design guidelines (11). These parameters were adhered to
during the design of monoplex assays so that the assays could be easily multi-
plexed after specificity and sensitivity testing was complete.
For the MTC and internal amplification control (IAC) assay, PCR primers
MTC_IAC Fw and MTC_IAC Rv (Table 1) were designed to amplify a 155-bp
fragment of the lepA gene for all members of the MTC and M. smegmatis. The
MTC_IAC Fw primer was located at positions 618 to 634 bp and the MTC_IAC
Rv primer was located at positions 754 to 772 bp of the M. tuberculosis H37Rv
lepA gene. For the M. tuberculosis and M. canettii assay, primers wbbl1_Fw and
wbbl1_Rv were designed to amplify a 146-bp fragment of the wbbl1 gene. The
wbbl1_Fw primer was located at positions 15 to 34 bp and the wbbl1_Rv primer
was located at positions 141 to 159 bp of the M. tuberculosis H37Rv wbbl1 gene.
Finally, the M. canettii-specific assay was designed to amplify a 128-bp fragment
of a 2,869-bp region of the genome identified in this study to be specific to M.
canettii (an M. canettii-specific assay could potentially be designed with sequence
from anywhere in this region). This 2,869-bp region of the genome has been
mapped to the M. tuberculosis H37Rv genome and is inserted between Rv0150c
(hypothetical protein) and Rv0151c (gene name, PE1; a proline-glutamate [PE]
family protein) at position 177,445 bp on the M. tuberculosis H37Rv genome.
All real-time PCR assays were initially tested in a monoplex format, evaluating
their specificity and sensitivity, using probes labeled with 6-carboxyfluorescein
(FAM) and black hole quencher 1 (BHQ1). After the monoplex real-time PCR
assays were optimized, three of the four assay probes were labeled with different
fluorescent dyes to allow multiplex real-time PCR. The MTC probe was labeled
with 4,4,7,2,4,5,7-hexachloro-6-carboxyfluorescein (HEX) and BHQ1, the M.
canettii-specific probe with carboxy-X-rhodamine (ROX) and BHQ2, and the
IAC probe with Cy5 and BHQ2.
Conventional PCR. Conventional PCR was performed using the sequencing
primers outlined in Table 1 on an iCycler iQ thermal cycler (Bio-Rad Labora-
tories Inc., CA). All reactions were carried out in a final volume of 50 l
containing 5 l 10 buffer (15 mM MgCl2), forward and reverse primers (final
concentrations, 0.2 M), 2 l Taq DNA polymerase (1 U/l; Roche Diagnostics,
Basel, Switzerland), 1 l deoxynucleoside triphosphate mix (10 mM de-
oxynucleoside triphosphate set; Roche Diagnostics), 2 l of template DNA, and
38 l nuclease-free water (Applied Biosystems/Ambion, TX). The cycling pa-
rameters consisted of initial denaturation at 95°C for 5 min, followed by 35 cycles
of denaturation at 95°C (1 min), amplification at 55°C (1 min), and extension at
72°C (1 min) and by a final elongation at 72°C for 10 min.
Sequencing. Nucleotide sequence data for real-time PCR assay design were
generated in this study or were obtained from either the National Center for
Biotechnology Information (NCBI) or the Sanger website (where partial nucle-
otide sequences for M. canettii, M. africanum, and M. microti were available). The
primers used for the real-time PCR assays were also used in conventional PCRs
to generate nucleotide sequence information for each of the assays developed. In
addition, sequencing primers were designed to span the full 2,869-bp M. canettii-
specific nucleotide sequence identified, to evaluate if this region is conserved in
all M. canettii strains tested in this study, and to identify potential diagnostics
target nucleotide sequences for probe design.
PCR products were generated as described above, followed by purification
using a High Pure PCR product purification kit (Roche Diagnostics). The puri-
fied PCR products were sequenced externally (Sequiserve, Vaterstetten, Ger-
many).
Development of IAC for real-time PCR. An IAC targeting the M. smegmatis
lepA gene was developed for the multiplex real-time PCR. Both the IAC and
MTC targets were amplified using the same primer set; however, the IAC probe,
targeting M. smegmatis, was labeled with Cy5, while the MTC probe was labeled
with HEX (Table 1). Titrations of MTC and IAC DNA were performed to
determine the optimum concentration of IAC target per reaction mixture such
that it was always detected without impacting detection of the primary MTC
target (17). An IAC concentration of 500 genome equivalents per reaction
mixture allowed the positive detection of the IAC at low concentrations or in the
absence of primary target.
The lepA gene was chosen as the target for the IAC because sufficient se-
quence heterogeneity exists between the M. smegmatis and MTC lepA gene
sequences for the design of independent, specific probes. There was also enough
homology in the sequence flanking these probe regions to design one set of
primers to amplify both MTC and IAC targets. This resulted in three rather than
four primer pairs in the multiplex PCR, reducing assay complexity.
Real-time PCR. Monoplex real-time PCR was performed on a LightCycler
(version 2.0) instrument (Roche Diagnostics) using a LightCycler TaqMan mas-
ter kit (Roche Diagnostics). A final volume of 20 l was used in each reaction
mixture, containing 5 master mix, forward and reverse primers (final concen-
trations, 0.5 mM), FAM-labeled probe (final concentration, 0.2 mM), and tem-
plate DNA (2 l), and the volume was adjusted to 20 l with the addition of
nuclease-free distilled H2O (dH2O). The cycling parameters consisted of incu-
bation for 10 min at 95°C to activate enzymes and denature DNA, followed by 50
cycles of 95°C for 10 s and 60°C for 30 s, followed by a cooling step at 40°C for
10 s. The temperature transition rate for all cycling steps was 20°C/s.
Multiplex real-time PCRs were carried out on the LightCycler 480 instrument
using a LightCycler 480 probes master kit (Roche Diagnostics). A final volume
of 40 l was used for each multiplex reaction mixture. The optimized master mix
contained 2 LightCycler 480 probes master (6.4 mM MgCl2), forward and
reverse primers (final concentrations, 0.5 M), FAM-labeled probe (final con-
centration, 0.4 M), HEX-, ROX-, and Cy5-labeled probes (final concentrations,
0.2 M), and template DNA (MTC, 2 l; IAC, 2 l; NTM, 10 l), and the
volume was adjusted to 40 l with the addition of nuclease-free dH2O. The
internal control DNA mixture was diluted to contain 500 genome equivalents per
2 l, and the NTM DNA consisted of 104 genome equivalents per 10 l.
The cycling parameters used were the same as those used on the LightCycler
2.0 instrument. The temperature transition rate, referred to as the ramp rate on
the LightCycler 480 instrument, was 4.4°C/s while heating and 2.2°C/s while
cooling. Prior to experimental analysis on the LightCycler 480 instrument, a color
compensation file was generated using the technical note outlined in the Ad-
vanced Software Functionalities of the operator manual (2).
Nucleotide sequence accession numbers. Partial wbbl1 gene nucleotide se-
quences generated in this study for the five M. canettii strains (see Table S1 in the
supplemental material) were deposited in GenBank with the following accession
numbers: HQ625205 through HQ625209. Nucleotide sequences generated in this
study for the proposed novel RDcanettii1 were also deposited in GenBank with the
following accession numbers HQ625200 through HQ625204.
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RESULTS
Diagnostics targets identification. The diagnostics nucleo-
tide sequence target identified in this study for detection of the
MTC in combination with detection of the IAC was lepA
(Rv2404c). LepA is an elongation factor required for accurate
and efficient protein synthesis capable of inducing backtrans-
location of mistranslocated tRNAs. The lepA gene is present in
all bacteria sequenced to date and codes for one of the most
conserved proteins in bacteria (55 to 68% amino acid sequence
similarity between bacteria), with a homologue (Guf1) being
found in higher organisms (32).
For the specific detection of M. tuberculosis and M. canet-
tii, a wbbl1 gene nucleotide sequence target (Rv3265c) was
identified. The wbbl1 gene encodes rhamnosyl transferase,
which inserts rhamnose into the cell wall and which is
thought to be essential for mycobacterial viability (24). Nu-
cleotide sequence analysis of members of the MTC revealed
a 12-bp region of the wbbl1 gene which is present only in M.
tuberculosis and M. canettii and which has been deleted in all
other members of the MTC.
The M. canettii-specific diagnostics nucleotide sequence tar-
get identified in this study is a region of the genome that
appears to be deleted in all other members of the MTC. This
2,869-bp region was discovered while RD12can was mapped to
the unfinished genome sequence of M. canettii available on the
Sanger website. This region appears to be a novel RD specific
for M. canettii. To date, the M. canettii genome is not anno-
tated; therefore, the function of the gene(s) in this region is
unknown. The M. canettii diagnostics target region identified
was BLAST analyzed and revealed similarity to a putative ATP
binding protein gene in Nocardioides species (query coverage,
52%; maximum indent, 73%). This region was sequenced using
the primers listed in Table 1 for the M. canettii strains used in
this study. Sequence analysis revealed 100% similarity between
the five strains and the sequence available on the Sanger web-
site.
Assay design and development. While the guidelines for
primer and probe design were adhered to as closely as possible,
the high GC content (60 to 65%) of the Mycobacterium species
did have an impact on assay design. The wbbl1-specific probe
was based on a region that was present in M. tuberculosis and
M. canettii and deleted in other members of the MTC and that
is very G/C rich, making probe design difficult. This probe was
labeled with FAM, and double the standard probe concentra-
tion (0.4 M/reaction mixture) was used to improve the end-
point fluorescence, sensitivity, and robustness of the assay.
Internal amplification control. In order for a result to be
considered valid using the multiplex real-time PCR assay de-
veloped in this study, a positive signal must be obtained in at
least one of the four detection channels on the LightCycler 480
instrument. If none of the assay targets or the IAC is detected,
the result is considered invalid and the assay must be repeated
(17, 28). In this study, M. smegmatis DNA is spiked into the
PCR master mix to act as an internal control target. Equally,
M. smegmatis cells could also be used as a process control,
when they are spiked into patient samples before total genomic
DNA extraction. This could then act as a control for both DNA
extraction and PCR efficiency when patient samples are tested.
Specificity of diagnostic assays. The specificity of each real-
time PCR assay was confirmed in both monoplex and multiplex
formats using the specificity panel listed in Tables S1 and S2 in
the supplemental material. The wbbl1 assay was specific for the
detection of the 26 M. tuberculosis and the 5 M. canettii strains.
Figure 1A shows the detection of six M. tuberculosis strains
(circles) and five M. canettii strains (triangles). The remaining
members of the MTC, the NTM, and other bacteria were not
detected. All 64 MTC strains were detected in the MTC assay
(Fig. 1B), and 44 NTM and 17 other bacteria were not de-
tected. The M. canettii assay was specific for the five M. canettii
isolates (Fig. 1C) and did not cross-react with the specificity
panel. The specificity of the IAC assay was tested using the
MTC panel and was specific for M. smegmatis DNA. As the
MTC and IAC assays are competitive, the IAC is detected only
at low concentrations or in the absence of primary target. In
Fig. 1B, the M. africanum 3 sample tested in the assay is
present at a lower concentration than the other members of
the MTC; hence, a stronger amplification signal is observed in
the Cy5 channel (IAC) with this sample (Fig. 1D, M. africanum
3 represented by diamonds). A simple interpretation of the
results that can be obtained from the multiplex real-time PCR
developed is outlined in Table 2.
Sensitivity of the assays. The limit of detection (LOD) of
each assay was evaluated in a monoplex real-time PCR format.
Genomic DNA was quantified and serial dilutions with from
200,000 to 2 genome equivalents were prepared, based on the
genome size of M. canettii (4,525,000 bp), which equates to
approximately 4.9 fg DNA per cell. M. canettii was chosen for
sensitivity testing of the multiplex assay, as it is detected in
each of the primary target assays (the M. tuberculosis/M. canet-
tii-, MTC-, and M. canettii-specific assays).
In the monoplex format, the dilution series was run in du-
plicate and a sensitivity of 2 to 20 M. canettii genome equiva-
lents was determined for each assay. In the multiplex format,
the lower limit of detection was established using probit re-
gression analysis. In this analysis, 12 replicates of each of 20,
15, 12, 10, 7.5, 4, 2, and 0.2 genome equivalents were evaluated.
LODs of 2.17, 2.20, and 0.73 genome equivalents for the M.
canettii/M. tuberculosis-, MTC-, and M. canettii-specific assays,
respectively, were determined with 95% probability. The IAC,
at a concentration of 500 genome equivalents per reaction
mixture, was detected in all samples tested.
DISCUSSION
In 1998, the Stop TB initiative was established with the
ultimate goal of obtaining a world free of TB. Within this
initiative, a core group, the New Diagnostics Working Group
(NDWG), was founded in an effort to establish new diagnostics
for TB. This working group, along with a number of collabo-
rators, such as the Foundation for Innovative New Diagnostics
(FIND), have launched a new web resource, Evidence-Based
Tuberculosis Diagnosis, which highlights the importance of
new diagnostics for the rapid and cost-effective detection of TB
(29).
At present, literature describing TB NAD assays, in addition
to commercially available TB NAD kits (5, 8, 16), is limited,
and the scope and capacity of these assays to differentiate the
MTC to the species level are also limited. For example, the
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GenoType MTBC kit (Hain Lifescience GmbH, Nehren, Ger-
many), which claims to differentiate the members of the MTC,
does not in fact differentiate between M. tuberculosis and M.
canettii or between M. africanum and M. pinnipedii (21). Re-
cently, a study by Pinsky and Banaei (31), which describes a
real-time PCR for differentiation of the MTC, fails to differ-
entiate M. tuberculosis and M. canettii and is also unable to
differentiate between M. africanum, M. microti, M. pinnipedii,
and M. caprae. A capability to identify the specific MTC spe-
cies causing infection is important for determining the appro-
priate therapeutic regimen for the patient (34).
The multiplex real-time PCR assay described in this study
uses novel nucleic acid diagnostics targets for the identification
of the MTC, M. tuberculosis, and M. canettii. The first novel
target identified was a lepA gene nucleotide sequence. This
target was used to detect the MTC and to develop the IAC for
the real-time PCR diagnostics assay. The second novel molec-
ular target identified and evaluated in this study was a wbbl1
gene nucleotide sequence target which enables the simulta-
neous detection of M. tuberculosis and M. canettii and which is
a target with the same diagnostics potential as the RD9 region
widely used for M. tuberculosis identification. The third novel
diagnostics target nucleotide sequence identified allowed the
differentiation of M. canettii from M. tuberculosis. As this nu-
cleotide sequence is present in the five M. canettii strains used
in this study and is 100% homologous, we propose this to be a
novel RD (RDcanettii1).
An M. canettii RD which represents a region of the genome
flanking RD12 which is deleted in M. canettii but present in M.
tuberculosis has previously been described by Huard et al. (18).
The study uses conventional PCR for differentiation of the
MTC, including M. tuberculosis and M. canettii, on the basis of
FIG. 1. (A) Real-time amplification curves for M. tuberculosis (circles) and M. canettii (triangles) using wbbl1 gene in FAM channel (483 to 533
nm); (B) amplification curves for all MTC using lepA gene in HEX channel (523 to 568 nm), with the nontemplate control, highlighted with circles
with lines; (C) amplification curves for M. canettii specific assay in ROX channel (558 to 610 nm), with the five M. canettii strains depicted with
triangles; (D) amplification curves for IAC in Cy5 channel (615 to 670 nm), with M. africanum 3 highlighted with diamonds through the
amplification curve. The reduction of the IAC signal is due to competition from high concentrations of primary target, resulting in competition
between the MTC and IAC assays.
TABLE 2. Result interpretation table
Diagnostics result profile
ResultFAM
(wbbl1
assay)
HEX
(MTC
assay)
ROX
(M. canettii
RD assay)
Cy5
(IACa)
   / M. canettii present
   / M. tuberculosis present
   / MTC (other than
M. canettii or
M. tuberculosis) present
    Not a member of MTC
    Result invalid and test must
be repeated
a The IAC is detected only in the presence of low concentrations of primary
target or in the absence of primary target.
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PCR product size. The method requires time-consuming mul-
tiple reactions and produces results that require detailed in-
terpretation. In the current study, we have identified a putative
new RD which is present in M. canettii but deleted in M.
tuberculosis and all other members of the MTC. As this region
is present only in M. canettii, the interpretation of results is less
complex.
The multiplex real-time PCR developed in this study is the
first hydrolysis probe-based diagnostic tool capable of rapid
detection of the MTC, combined with the detection and dif-
ferentiation of M. tuberculosis and M. canettii using novel tar-
gets, to be described. This rapid, specific, and sensitive multi-
plex real-time PCR assay produces a diagnostic result in less
than 1 h after DNA extraction. These novel genetic markers
will be further optimized and validated against a more exten-
sive range of clinical isolates, in addition to clinical samples, in
the future.
While the current study has focused on identifying novel
nucleotide sequence diagnostics targets and the development
of a multiplex real-time PCR for differentiation of M. tubercu-
losis and M. canettii, work has begun in the Microbiology lab-
oratory of the National University of Ireland, Galway, on de-
veloping a series of nucleic acid-based diagnostics assays with
the ability to differentiate all species of the MTC. For example,
there is a requirement to differentiate infection caused by both
M. bovis and M. bovis BCG from the remainder of the mem-
bers of the MTC, as they, like M. canettii, are intrinsically
resistant to PZA (35).
Ultimately, there will be a requirement to transfer this set of
assays to a platform with a capability of detecting and differ-
entiating the MTC in a single-test diagnostics format. For
example, the design of a microarray utilizing these novel MTC
diagnostics targets, in combination with diagnostics targets for
the determination of MTC drug resistance, could be signifi-
cantly advantageous. This rapid diagnostics approach would
provide the clinician with important information about the
optimal therapeutic regimen required for an infected patient
while at the same time provide the clinical laboratory with
unambiguous MTC epidemiological data.
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